Sarah Hughes to Dideoxynucleosides
This is a "connection" page, showing publications Sarah Hughes has written about Dideoxynucleosides.
Connection Strength
0.552
-
Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat. 2008 Apr-Jun; 7(2):121-9.
Score: 0.304
-
Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010 Oct 15; 51(8):963-72.
Score: 0.091
-
Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, Hughes SH, Yeo JM, Lapierre DH. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009 May 01; 51(1):20-8.
Score: 0.082
-
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, J?gel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008 Feb 07; 358(6):568-79.
Score: 0.075